低分子肝素联合拉贝洛尔治疗子痫前期的研究进展

To Evaluate the Efficacy of Low Molecular Weight Heparin Combined with Labetalol in the Treatment of Preeclampsia

子痫前期(preeclampsia, PE)是与妊娠相关的多系统疾病,临床表现为妊娠20周后发生的高血压、蛋白尿、肝肾功能损害和胎盘功能障碍等,严重危及母胎生命安全,是导致我国孕产妇围产期发病率和死亡率增加的主要原因。目前考虑子痫前期不良妊娠结局的发生与妊娠期高凝状态相关,故临床上常使用降压药物及低剂量抗凝药物等进行治疗。本文对低分子肝素联合拉贝洛尔对子痫前期的疗效评价进行综述。

Preeclampsia (PE) is a pregnancy-related multisystem disease, characterized by hypertension, proteinuria, liver and kidney dysfunction and placental dysfunction after 20 weeks of gestation, which seriously endanger the life of the mother and fetus and is the main cause of increasing per-inatal morbidity and mortality of pregnant women in China. At present, it is considered that the occurrence of adverse pregnancy outcomes of preeclampsia is related to hypercoagulable state during pregnancy, so antihypertensive drugs and low-dose anticoagulant drugs are used for clinical treatment. This article reviews the efficacy of low molecular weight heparin combined with labetalol in the treatment of preeclampsia.